• For investors wondering if Krystal Biotech at around US$296.70 is still offering value or if the easy gains are behind it, this article walks through what the current price may be implying.
• The stock has shown strong share price moves, with returns of 13.1% over 7 days, 12.4% over 30 days, 20.2% year to date, 116.3% over the last year, 228.5% over 3 years, and 374.4% over 5 years.
• These price moves sit against a backdrop of ongoing attention on Krystal Biotech's position in the pharmaceuticals and biotech space and investor interest in how its pipeline and approvals might shape its future. Coverage has focused on how the company fits into broader biotech trends and what that could mean for risk and opportunity around the stock.
• Krystal Biotech currently scores 2 out of 6 on our valuation checks for potential undervaluation, as shown by its valuation score. Next, you will see how traditional methods like multiples and cash flow models line up, before finishing with a more complete way to think about what the stock might be worth.

Krystal Biotech scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Krystal Biotech Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s dollars, aiming to estimate what the entire business could be worth right now.

For Krystal Biotech, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve months free cash flow is about $235.6 million. Analyst input and extrapolated estimates point to free cash flow of $292 million in 2026 and $772 million by 2030, all in $. Beyond the first five years, Simply Wall St extrapolates the projections to build a full 10 year cash flow path.

When these projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $804.91 per share. Compared with the current share price of around $296.70, the DCF output suggests the stock may be trading below this estimated value by about 63.1%.

Result: POTENTIALLY UNDERVALUED BASED ON THIS MODEL

Our Discounted Cash Flow (DCF) analysis suggests Krystal Biotech is undervalued by 63.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Krystal Biotech Price vs Earnings

For profitable companies like Krystal Biotech, the P/E ratio is a useful way to relate what you pay for the stock to what the company currently earns per share. It gives you a quick sense of how many dollars investors are paying for each dollar of earnings.

What counts as a reasonable P/E will usually depend on expectations for future earnings growth and how risky those earnings are perceived to be. Higher expected growth or lower perceived risk can support a higher P/E, while lower growth or higher risk tend to justify a lower P/E.

Krystal Biotech currently trades on a P/E of 38.87x. That is above the Biotechs industry average of 17.76x and the peer group average of 24.98x. Simply Wall St’s Fair Ratio for Krystal Biotech is 21.31x, which is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and company specific risks.

Compared with simple peer or industry comparisons, the Fair Ratio aims to be more tailored to the company’s own profile, since it incorporates growth, risk, profitability, sector and size in a single figure.

With a current P/E of 38.87x versus a Fair Ratio of 21.31x, the stock screens as trading above this Fair Ratio estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Krystal Biotech Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a clear story about Krystal Biotech to the numbers you care about, such as fair value, future revenue, earnings and margins, and to see how that story stacks up against other investors.

Each Narrative on Simply Wall St links a company story, such as confidence in global Vyjuvek launches and oncology and respiratory pipeline progress or concern about reimbursement pressure, treatment volatility and concentration risk, to a specific financial forecast and then to a fair value estimate. You can compare this directly with the current price to help judge whether the stock looks expensive or cheap on that story.

Because Narratives sit inside the Community page and are used by millions of investors, you can quickly see how a more optimistic view on Krystal Biotech, with a fair value around US$371, and a more cautious view, with a fair value around US$241, differ from the consensus near US$315. Those Narratives update automatically as new earnings, news or clinical milestones, such as RMAT designation for KB707, are incorporated into the underlying forecasts.

For Krystal Biotech, we will make it really easy for you with previews of two leading Krystal Biotech Narratives:

Fair value on this bullish narrative: US$315 per share

Implied undervaluation vs. last close: about 5.8% below that fair value

Revenue growth assumption: 36.4% a year

• This narrative assumes Vyjuvek international launches and a broader pipeline across lung, ophthalmology, oncology and aesthetics expand revenue beyond a single product.
• It also builds in high margin potential supported by in-house manufacturing, a 93% gross margin profile and improving operating leverage.
• It recognises risks around Vyjuvek concentration, reimbursement decisions, rising SG&A and evolving gene therapy competition and regulation.

Fair value on this cautious narrative: US$241 per share

Implied overvaluation vs. last close: about 23.1% above that fair value

Revenue growth assumption: 27.0% a year

• This narrative focuses on Vyjuvek reliance, with unpredictable patient treatment patterns, pricing pressure and reimbursement risk affecting revenue visibility and margins.
• It flags higher cost and execution risk as Krystal Biotech pushes into new indications, ramps R&D and depends on successful clinical readouts.
• It highlights potential headwinds from competition, DOJ scrutiny on genetic testing, and ongoing cash and dilution risk if spending stays elevated.

If you want to see how these bullish and bearish stories are built from the full set of assumptions, forecasts and risks, it may be useful to step through the Narratives side by side so you can decide which feels closer to your own view on Krystal Biotech.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Krystal Biotech on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Krystal Biotech? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.